Independent directory Public ClinicalTrials.gov records United States
Location Directory

Clinical trials in Portland, Oregon

This page shows live ClinicalTrials.gov search results for Portland, Oregon, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 20, 2026, 11:31 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
9384
Shown on this page
12
Current sort
Recently updated
Location scope
Portland, OR
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Portland, Oregon. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 961–972 of 9,384 matching trials in Portland, OR.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Live official records

Open in full search
Conditions
Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms
Interventions
Solriamfetol 150 MG, Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
40
States / cities
Tucson, Arizona • Bellflower, California • Chino, California + 33 more
Conditions
Dermatitis Atopic
Interventions
Amlitelimab, Placebo, Topical corticosteroids, Topical tacrolimus or pimecrolimus
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
43
States / cities
Birmingham, Alabama • Scottsdale, Arizona • North Little Rock, Arkansas + 36 more
Conditions
Symptomatic Hypertrophic Cardiomyopathy (HCM)
Interventions
Aficamten (5 - 20 mg)
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years to 85 Years
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
57
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 43 more
Conditions
Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastroesophageal Junction Carcinoma
Interventions
Itraconazole
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
7
States / cities
Palo Alto, California • Ann Arbor, Michigan • Durham, North Carolina + 4 more
Conditions
Dermatitis, Atopic
Interventions
Dupilumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
858 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
93
States / cities
Birmingham, Alabama • Gilbert, Arizona • Fountain Valley, California + 83 more
Conditions
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Lymphoscintigraphy, Magnetic Resonance Imaging, Ramucirumab, Tepotinib
Procedure · Biological · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Minutes and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
278
States / cities
Daphne, Alabama • Fairhope, Alabama • Mobile, Alabama + 232 more
Conditions
Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer, Cervical Cancer
Interventions
SKB264
Drug
Lead sponsor
Klus Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
10
States / cities
Glendale, California • Los Angeles, California • Sarasota, Florida + 7 more
Conditions
Cystic Fibrosis
Interventions
VX-121/TEZ/D-IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
822 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
72
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 65 more
Conditions
Pyoderma Gangrenosum
Interventions
topical ruxolitinib 1.5% cream
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 99 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Breast Cancer
Interventions
Arm A: Gedatolisib + Palbociclib + Fulvestrant, Arm B: Ribociclib + Fulvestrant, Arm C: Gedatolisib + Palbociclib + Letrozole, Arm D: Ribociclib + Letrozole
Drug
Lead sponsor
Celcuity Inc
Industry
Eligibility
18 Years and older
Enrollment
1,180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
30
States / cities
Jonesboro, Arkansas • Little Rock, Arkansas • Duarte, California + 27 more
Conditions
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Lineage Acute Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia of Ambiguous Lineage
Interventions
revumenib, cobicistat
Drug
Lead sponsor
Syndax Pharmaceuticals
Industry
Eligibility
30 Days and older
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
22
States / cities
Duarte, California • Los Angeles, California • Palo Alto, California + 17 more
Conditions
Lymphatic Malformations
Interventions
Alpelisib, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
0 Years to 100 Years
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
18
States / cities
Oakland, California • Orange, California • Palo Alto, California + 13 more